Details of the Drug Pharmacogenomic Perturbation Atlas

General Information of Drug (ID: DM6GTMD)

Drug Name
ADX-48621 Drug Info
Synonyms
Dipraglurant; 872363-17-2; UNII-CV8JZR21A1; ADX48621; CV8JZR21A1; CHEMBL2346738; 6-fluoro-2-[4-(2-pyridinyl)-3-butyn-1-yl]-Imidazo[1,2-a]pyridine; Dipraglurant [INN]; ADX-48621; SCHEMBL103033; GTPL6452; C16H12FN3; DTXSID90236230; BCP23706; BDBM50431705; ZINC72266314; 3590AH; 6-Fluoro-2-(4-(pyridin-2-yl)but-3-yn-1-yl)imidazo(1,2-a)pyridine; AKOS030526956; SB16993; DB12733; CS-0690; NCGC00351745-02; HY-14859; DB-076892; FT-0705373; J3.560.334D; W-5761; ADX 48621;ADX48621;ADX-48621
Cross-matching ID
PubChem CID
44557636
ChEBI ID
CHEMBL2346738
CAS Number
CAS 872363-17-2
TTD Drug ID
D0I5TL

Consensus Signature of Drug Pharmacogenomic Perturbation (DPP)
Term Name NES FDR q-val Tag % Leading Edge Genes
Rheumatoid arthritis 2.30 0.00e+0 78/93 (83.87%) MMP1;CXCL2;CXCL1;...
TNF signaling pathway 2.27 0.00e+0 103/112 (91.96%) CXCL2;CXCL1;ICAM1;...
IL-17 signaling pathway 2.24 0.00e+0 84/94 (89.36%) MMP1;CXCL2;CXCL1;...
Steroid biosynthesis 2.00 2.71e-3 19/20 (95%) MSMO1;CYP51A1;EBP;...
Viral protein interaction with cytokine and cytokine re... 1.96 4.33e-3 84/100 (84%) CXCL2;CXCL1;CXCL8;...
Antigen processing and presentation 1.85 1.99e-2 60/78 (76.92%) HSPA2;CD74;HSPA8;...
Spliceosome 1.79 3.09e-2 101/150 (67.33%) HSPA2;PRPF4;HSPA8;...
Ribosome 1.79 2.71e-2 113/158 (71.52%) RPS5;RPL35A;RPL26;...
Graft-versus-host disease 1.78 2.53e-2 32/42 (76.19%) HLA-DRA;HLA-B;HLA-A;...
Type I diabetes mellitus 1.75 3.03e-2 38/43 (88.37%) HLA-DRA;HLA-B;HLA-A;...
Legionellosis 1.75 2.95e-2 51/57 (89.47%) CXCL2;CXCL1;CXCL8;...
Epithelial cell signaling in Helicobacter pylori infect... 1.75 2.71e-2 62/70 (88.57%) CXCL2;CXCL1;CXCL8;...
×

Pharmacogenomic Perturbation Across Diseases and Tissues

Breast
Breast adenocarcinoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
MCF7 CVCL_0031 Homo sapiens 0.01uM - 10uM 24H
MDA-MB-231 CVCL_0062 Homo sapiens 0.01uM - 10uM 24H
Breast epithelium
Normal
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
MCF-10A CVCL_0598 Homo sapiens 0.01uM - 10uM 24H
Cervix
Cervical adenocarcinoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
HeLa CVCL_0030 Homo sapiens 0.01uM - 10uM 24H
Colon
Colorectal adenocarcinoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
HT-29 CVCL_0320 Homo sapiens 0.01uM - 10uM 24H
Kidney
Normal (Immortalized)
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
HA1E CVCL_0284 Homo sapiens 0.01uM - 10uM 24H
Normal (Transformed)
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
HEK293 CVCL_0045 Homo sapiens 0.01uM - 10uM 24H
Lung
Lung adenocarcinoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
A549 CVCL_0023 Homo sapiens 0.01uM - 10uM 24H
Pancreas
Pancreatic carcinoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
YAPC CVCL_1791 Homo sapiens 0.01uM - 10uM 24H
Peripheral blood
Acute monocytic leukemia
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
THP-1 CVCL_0006 Homo sapiens 0.01uM - 10uM 24H
T-cell acute lymphoblastic leukemia
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
Jurkat CVCL_0367 Homo sapiens 0.01uM - 10uM 24H
Prostate
Prostate carcinoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
PC-3 CVCL_0035 Homo sapiens 0.01uM - 10uM 24H
Skin
Melanoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
A-375 CVCL_0132 Homo sapiens 0.01uM - 10uM 24H